Validated anxiety assessments among pediatric patients with peanut allergy on oral immunotherapy

被引:2
|
作者
Kaman, Kelsey [1 ,4 ]
Dhodapkar, Meera [2 ]
Shabanova, Veronika [2 ]
McCollum, Sarah [2 ]
Factor, Jeffrey [1 ,3 ]
Leeds, Stephanie [2 ]
机构
[1] Connecticut Asthma & Allergy Ctr, Hartford, CT USA
[2] Yale Sch Med, New Haven, CT USA
[3] New England Food Allergy Treatment Ctr, Hartford, CT USA
[4] Connecticut Asthma & Allergy Ctr, 836 Farmington Ave 207, Hartford, CT 06119 USA
关键词
QUALITY-OF-LIFE; FOOD ALLERGY; DISPARITIES; MANAGEMENT; SYMPTOMS; CHILDREN; STRESS; IMPACT;
D O I
10.1016/j.anai.2023.01.028
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Although efficacy, safety, and quality of life measures associated with peanut oral immunotherapy (OIT) have been studied, the relationship between peanut OIT and clinical anxiety has not yet been evaluated. The latter is important to help providers and families have an improved shared medical decision discussion around the benefits of initiating OIT.Objective: To investigate the relationship between undergoing OIT and anxiety in patients with peanut allergy.Methods: In this prospective cross-sectional cohort study, using validated and age-appropriate anxiety scales administered with electronic survey questionnaires, we used generalized linear regressions to compare anxiety between patients undergoing OIT and similar patients with peanut allergy but not on OIT (controls).Results: In the younger cohort (<7 years, n = 80), there was generally a low prevalence of diagnosable anxiety across patients on OIT and controls. In the older cohort (>7 years, n = 125), there was a higher prevalence of anx-iety but no clinically meaningful difference between anxiety scores of patients on OIT and controls. In the older cohort, patients with asthma were more likely to have higher mean anxiety scores (P = .04), as were female patients compared with male patients (P = .004). A subanalysis of separation anxiety scores in the older cohort revealed that younger age (7-12 years vs >12 years, P < .001), non-White race (P = .04), and eczema (P = .02) were found to be meaningful predictors of higher scores. A subanalysis of social anxiety on the older cohort pointed toward non-White race as a meaningful predictor of higher scores (P < .02).Conclusion: The clinical implications of these findings suggest that allergists should particularly consider screen-ing children with food allergy for anxiety and anxiety subtypes among patients who are non-White, female, or have asthma.& COPY; 2023 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:657 / 663
页数:7
相关论文
共 50 条
  • [41] Current management and use of oral immunotherapy in the United States for patients with peanut allergy
    Blaiss, Michael S.
    Tilles, Stephen
    Petroni, Daniel
    Zigmont, Ellen
    Cassese, Marie
    Kwak, Brian
    Georgitseas, Nicholas
    Liebermann, Jay
    ALLERGY AND ASTHMA PROCEEDINGS, 2019, 40 (04) : 214 - 220
  • [42] Post-hoc Analysis: Oral Immunotherapy effective for Patients with Peanut Allergy
    Kempe, Sabrina
    ALLERGO JOURNAL, 2023, 32 (04) : 12 - 14
  • [43] CURRENT MANAGEMENT AND USE OF ORAL IMMUNOTHERAPY (OIT) FOR PEANUT ALLERGY IN US PATIENTS
    Blaiss, M.
    Petroni, D.
    Tilles, S.
    Zigmont, E.
    Bennett, K.
    Venugopal, A.
    Cassese, M.
    Georgitseas, N.
    Lieberman, J.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2017, 119 (05) : S80 - S80
  • [44] Oral peanut immunotherapy for peanut allergic patients
    Nash, S. D.
    Steele, P. H.
    Kamilaris, J. S.
    Pons, L.
    Kulis, M.
    Lee, L. A.
    Althage, K.
    Christie, L.
    Scurlock, A. M.
    Jones, S. M.
    Burks, A. W.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2007, 119 (01) : S158 - S158
  • [45] Investigation of peanut oral immunotherapy with CpG/peanut nanoparticles in a murine model of peanut allergy
    Srivastava, Kamal D.
    Siefert, Alyssa
    Fahmy, Tarek M.
    Caplan, Michael J.
    Li, Xiu-Min
    Sampson, Hugh A.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 138 (02) : 536 - +
  • [46] Threshold Dose For Peanut Allergy During Peanut Oral Immunotherapy Procedure In Children
    Christie, L.
    Althage, K. A.
    Scurlock, A. M.
    Perry, T. T.
    Pons, L.
    Steele, P.
    Kamilaris, J.
    Jones, S. M.
    Burks, A. W.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 123 (02) : S77 - S77
  • [47] Assessment of Social Limitations in Children with Peanut Allergy Undergoing Peanut Oral Immunotherapy
    Costanza, Lucia
    Rosenberg, Chen
    Shreffler, Wayne
    Rotter, Nancy
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) : AB41 - AB41
  • [48] Combined Probiotic and Peanut Oral Immunotherapy for the Treatment of Peanut Allergy: A Randomised Trial
    Tang, Mimi L. K.
    Ponsonby, Anne-Louise
    Orsini, Francesca
    Tey, Dean
    Robinson, Marnie
    Su, Ee Lyn
    Licciardi, Paul
    Burks, A. Wesley
    Donath, Susan
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 135 (02) : AB156 - AB156
  • [49] ORAL IMMUNOTHERAPY IN CHILDREN WITH PEANUT ALLERGY ALONE OR WITH OTHER FOOD ALLERGY IN PALISADE
    Du Toit, G.
    Nilsson, C.
    Vereda-Ortiz, A.
    Norval, D.
    Scurlock, A.
    Ciaccio, C.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 129 : S59 - S60
  • [50] Longitudinal antibody responses to peanut following probiotic and peanut oral immunotherapy in children with peanut allergy
    Hsiao, Kuang-Chih
    Ponsonby, Anne-Louise
    Ashley, Sarah
    Lee, Cassandra Yuen Yan
    Jindal, Lalita
    Tang, Mimi L. K.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2022, 52 (06): : 735 - 746